Zepbound at 3 months: what the label reports
The Zepbound label does not tabulate a three-month weight-loss estimate. It reports results at weeks 36, 72 and 88, alongside graphs showing changes over time. At twelve weeks, a patient may be taking 5 mg as a maintenance dose or increasing toward a higher dose, depending on treatment response and tolerability.
Reviewed by Ellis Brandt. Sources checked September 2026.
This guide draws on the cited FDA-approved prescribing information and other FDA sources. It is not medical advice; discuss treatment with your clinician. See the medical disclaimer.
What the label measures, and when
Four trials sit behind the weight indication, and every one of them was built around a long run. Studies 1, 2 and 3 assessed weight after 72 weeks of treatment, with at least 52 of those weeks at the maintenance dose. Study 4 ran an open-label 36-week lead-in and then a randomized withdrawal out to week 88.
Drag the table sideways to read the remaining columns.
| Point in treatment | What the label reports | The trial behind it |
|---|---|---|
| Week 12 | No tabulated treatment result | The label does not tabulate a three-month weight-loss estimate for Zepbound treatment. Its stated 12-week result is from Study 3's lead-in, before the drug: an average 6.9% loss from an intensive diet and exercise program. |
| Week 36 | 20.9% average loss | Study 4's open-label lead-in: 670 adults took Zepbound, escalated to a 10 mg or 15 mg maximum tolerated dose, and lost an average of 20.9% of their body weight over 36 weeks before the trial's randomized part began. |
| Week 72 | 15.0% at 5 mg, 19.5% at 10 mg, 20.9% at 15 mg | Study 1, against 3.1% on placebo, in 2,539 adults with obesity or overweight and no type 2 diabetes. Study 2, in adults with type 2 diabetes, reports 12.8% at 10 mg and 14.7% at 15 mg against 3.2%. |
| Week 88 | What happens when it stops | Study 4 again: after the 36-week lead-in, patients who kept taking Zepbound lost a further 5.5% by week 88, while those switched to placebo regained 14.0%. |
The label does draw the weeks in between. Figures 3 through 6 plot weight against time from the first dose, but they are pictures printed in the document with no table of intermediate values beside them. This page does not estimate a precise twelve-week result from those curves. The by-dose results at week 72 are set out in full on Zepbound at 5, 10 and 15 mg.
Dose increases and maintenance at 12 weeks
For weight reduction and long-term maintenance, the label lists 5 mg, 10 mg and 15 mg once weekly as maintenance options. The prescriber selects a dose based on treatment response and tolerability; increasing to the highest dose is not required.
Treatment starts at 2.5 mg once weekly for four weeks, then increases to 5 mg. The 2.5 mg dose is for starting treatment, not maintenance. Further increases may be made in 2.5 mg steps after at least four weeks at the current dose. If a prescriber increases the dose at each earliest permitted step, the patient would take 7.5 mg during weeks 9 to 12. That is one possible schedule, not a description of what most patients take.
A dosing schedule cannot tell you how much weight you will lose in three months. The four products’ schedules sit side by side on the dose escalation schedules, and what the labels report about side effects during dose increases is on side effect rates, label by label.
The one 12-week number in the document
One twelve-week figure does appear in the label, and it is not a Zepbound result. Study 3 opened with a 12-week intensive lifestyle program before any drug: eight sessions with a dietitian, a target of 1,200 kcal a day for women and 1,500 for men, and at least 150 minutes of exercise a week. The 579 patients who went on to be randomized had lost an average of 6.9% of their body weight by the end of it.
This is a lifestyle-program result, not a three-month estimate for Zepbound. Only patients who lost at least 5% during those weeks entered the drug phase, so the figure describes a selected group, and the 18.4% they went on to lose over the next 72 weeks is measured from the day the drug started, not from the day they walked in.
Sources
Drag the table sideways to read the remaining columns.
| Label | Applicant on the label | SPL version | Label effective date | Where it was read |
|---|---|---|---|---|
| Zepbound (tirzepatide) | Eli Lilly and Company | 40 | 2026-08-28 | DailyMed, set id 487cd7e7-434c-4925-99fa-aa80b1cc776b |
Every trial figure is from section 14.1 of the Zepbound label; dosing and maintenance information is from sections 2.1–2.2. Every figure and quotation comes from the label’s own tables and text. Each label is the FDA-approved version that was current when it was read in September 2026, identified in the table by its version number and effective date.
See the providers
What a month of treatment costs is a separate question from what it does. The boards list who sells tirzepatide and what each seller publishes about the price.
- Tirzepatide providersprovider board
Compare tirzepatide plans, pharmacy details and cancellation terms.
- Semaglutide providersprovider board
Compare semaglutide plans, pharmacy details and cancellation terms.
More, read from the same labels
- First-year GLP-1 costsresearch guide
A low monthly headline does not tell you what a year of treatment will cost. Compare the same medication and service package, then separate the total you expect to spend from the amount you must pay before treatment begins.
- Cancellation and refundsresearch guide
Canceling future membership charges, stopping an upcoming medication order and requesting a refund are three different requests. Get a written answer for each one that applies to you.
- Insurance denial documentsresearch guide
The next step depends on why coverage was denied. A missing document, a formulary restriction and an excluded benefit are different problems. Start with the written decision before paying someone to submit another request.
- Savings and cash-pay eligibilityresearch guide
A manufacturer savings card and a self-pay offer can have different eligibility rules, even for the same medicine. Match the offer to your coverage and exact product before using its advertised price in your budget.
- Verify your GLP-1 pharmacyresearch guide
The website taking your payment, the clinician prescribing and the pharmacy dispensing may be different businesses. Identify each one. A recognizable brand or a reassuring badge does not tell you who will fill the prescription.
- Changing GLP-1 providersresearch guide
Before ending your current service, establish what the new practice needs, what it will charge and when it can evaluate you. Transferring your records does not guarantee that another clinician will continue the same prescription.
- Weight regain after stoppingresearch guide
Weight regain occurred after treatment withdrawal in studies of semaglutide and tirzepatide. The findings support planning follow-up and affordability before an interruption, but they do not predict exactly what will happen to one person.
- Semaglutide vs tirzepatideresearch guide
What the four FDA-approved labels say each molecule is, what each is approved to treat, and where the two differ.
- How they workresearch guide
The receptor each molecule switches on, what the labels say that does to appetite, blood sugar and the stomach, and why one dose lasts a week.
- Is Ozempic insulin?research guide
What the Ozempic label calls semaglutide, how that differs from insulin, and where insulin appears on these labels as a separate medicine.
- Zepbound vs Ozempicresearch guide
Four brand names, two molecules and two kinds of approval: which of these products are the same drug, and what each one is actually approved to do.
- Dose escalation schedulesresearch guide
The starting dose, the escalation interval and the maximum dose each label sets, and why they are not interchangeable.
- Side effect ratesresearch guide
What each label reports for nausea, vomiting, diarrhea and constipation — and the sentence every label prints above those numbers.
- Hair lossresearch guide
Which labels report hair loss, the rate against placebo where a trial measured it, and why two of them put no number on it.
- Fatigue and tirednessresearch guide
Which labels list fatigue, the rate against placebo where a trial measured it, and what each label counts as fatigue.
- Missed dose rulesresearch guide
The window each label gives for a late dose, and the minimum gap it requires when the injection day changes.
- Drug interactionsresearch guide
Insulin and sulfonylureas, oral medications, and the oral-contraceptive precaution that appears on two of these four labels and not the other two.
- Buying one onlineresearch guide
The agency's own warning signs for a telehealth GLP-1 seller, its 28-day vial rule, and what it says about drugs that arrive warm.
- Zepbound by doseresearch guide
What each Zepbound dose achieved in the trials printed in its label, what the label says about choosing a maintenance dose, and what the higher doses cost in side effects.
- Injecting tirzepatideresearch guide
The injection sites, the rotation rule and the steps for the single-dose pen, the KwikPen and the vial and syringe, exactly as the FDA-approved Instructions for Use give them.
- Refrigeration and storageresearch guide
How cold each pen is kept, how many days it can spend at room temperature, and what the labels say about heat and freezing.
- Who should not take oneresearch guide
The boxed warning every one of these labels carries, the two contraindications, and which warnings appear on which product.
Results reported in the label
| Week 12 | not tabulated |
|---|---|
| Week 36 | 20.9% average |
| Week 72 | 15.0% to 20.9% |
| Week 88 | what stopping does |
Section 14.1, Zepbound label version 40, effective 2026-08-28.